Showing results (91-100 of 119) with videos related to
Sort By:
Pageof 12
European Urology Open Science|November 10, 2022
Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer RegistryAnders Bjartell, Luis Costa, Gero Kramer, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 20, 2025
PSMA-Directed PET/MRI Enables Noninvasive Diagnosis and Prognosis in Patients with Increased PSA Levels: Results from the Prospective Randomized RAPID TrialMarkus Hartenbach, Sazan Rasul, Bernhard Grubmüller, et al.International Journal of Cancer|June 11, 2022
Proteome profiling of enzalutamide-resistant cell lines and serum analysis identified ALCAM as marker of resistance in castration-resistant prostate cancerAnita Csizmarik, Dávid Keresztes, Nikolett Nagy, et al.Prostate Cancer and Prostatic Diseases|August 26, 2023
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancerAnita Csizmarik, Nikolett Nagy, Dávid Keresztes, et al.Clinical Genitourinary Cancer|October 29, 2017
The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate CancerDaniel Heinrich, Jasmin Bektic, Andries M Bergman, et al.BMC Cancer|July 2, 2025
Final analysis of ArtemisR, a European real-world retrospective study of apalutamide for the treatment of patients with metastatic hormone-sensitive prostate cancerMartin Boegemann, Mostefa Bennamoun, Louis Marie Dourthe, et al.World Journal of Urology|August 1, 2023
Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancerKatharina Rebhan, Philipp D Stelzer, Benjamin Pradere, et al.Urologic Oncology|March 15, 2016
Validation of lymphovascular invasion is an independent prognostic factor for biochemical recurrence after radical prostatectomyHarun Fajkovic, Romain Mathieu, Ilaria Lucca, et al.Journal of Cellular and Molecular Medicine|December 31, 2021
Comparative proteome analysis identified CD44 as a possible serum marker for docetaxel resistance in castration-resistant prostate cancerDávid Keresztes, Anita Csizmarik, Nikolett Nagy, et al.The New England Journal of Medicine|October 1, 2019
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate CancerRonald de Wit, Johann de Bono, Cora N Sternberg, et al.Pageof 12